Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with SBRT in Early Stage NSCLC
NCT03383302Phase 2Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Feb 2018
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Royal Marsden NHS Foundation Trust. Started Feb 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03383302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03383302.